Project Grant HT94252310554
Award Date
7/15/23
Completion Date
7/14/26
Dollars Obligated
$1.1M
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Madison, WI 53715, USA
Similar Awards
This $1,146,270 Project Grant was awarded by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to the University of Wisconsin System to target a lipid kinase regulator of nuclear Akt in breast cancer. The project aims to transform health care for Service Members and the American public through innovative and impactful research, with a focus on medical solutions for the battlefield. The grant will fund research activities at the University of...
The University of Wisconsin-Madison will receive $1,145,080 under a three-year Project Grant award from the Department of the Army Medical Command's Military Medical Research and Development program. The grant will fund research from February 2021 to January 2024 to therapeutically target a lipid kinase regulator of mutant p53 in breast cancer. Through this award provided by the CFDA 12.420 program, the University of Wisconsin-Madison aims to investigate medical solutions for the battlefield and...
This federal Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides $155,500.00 to the University of Wisconsin - Madison to develop a model to study tumor-normal cell interaction in vitro for high-throughput drug screening. The award period runs from December 1, 2024 to November 30, 2025. This grant supports innovative biomedical research focused on transforming healthcare for military service members and the...
This federal Project Grant award, valued at $785,833.00, was provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The award supports research targeting immunotherapy-resistant lesions to eradicate oligometastatic prostate cancer, with a performance period from September 1, 2024 to August 31, 2027. The primary awardee is the University of Wisconsin System, specifically the University of Wisconsin-Madison's Research and Sponsored Programs...
The University of Wisconsin System was awarded a $995,076 project grant by the U.S. Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to support the development of new agents for the treatment of hormone receptor positive and HER2 positive breast cancer. The grant was awarded on Dec 15, 2023 and is scheduled for completion on Dec 14, 2026. As part of this project, the University of Wisconsin System has sub-awarded funding to Loyola University of...
This federal Project Grant award of $459,747.00, awarded by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), supports research at the University of Wisconsin-Madison to define the effect of copy number amplification on the regulation of oncogenes in high-grade serous ovarian carcinoma. The research will examine the contributions of superenhancers at the 8q22 region, with the goal of advancing scientific understanding and potential treatment...
This federal Project Grant award, issued by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program, provides $1,555,000.00 to the University of Wisconsin System to conduct research focused on "Population Modeling to Optimize Equitable Ovarian Cancer Outcomes." The award, effective from April 15, 2025 to April 14, 2029, will support advanced scientific investigations into innovative approaches for disease prevention, diagnosis, treatment, and...
The University of Wisconsin-Madison will receive $1.17 million over four years through a Project Grant from the Defense Health Agency under the Military Medical Research and Development program. The grant will fund research to interrogate the intersection of prostate-specific membrane antigen and PI3K pathway signaling as a novel treatment approach for treatment-resistant prostate cancer. The University will investigate medical solutions for prostate cancer with the goals of transforming patient...
The University of Wisconsin-Madison will receive $1,377,598 under a three-year Project Grant from the Defense Health Agency to investigate medical solutions for targeting dysregulated histone-modifying enzymes driving prostate cancer cell survival after androgen deprivation therapy. The grant is part of the Military Medical Research and Development program (CFDA 12.420), which supports biomedical research to transform military and public health care through innovative solutions for battlefield...
The Defense Health Agency has awarded a $862,751 Project Grant to the University of Wisconsin-Milwaukee (UWM) under the Military Medical Research and Development program (CFDA 12.420). The grant, effective June 1, 2024 through May 31, 2027, will fund a research project to study the "Impact of Recent Childbirth on Breast Cancer Prognosis and Tumor Molecular Phenotypes Among Young Black and White Women." This grant supports UWM's ongoing biomedical research initiatives focused on...